Market Overview

UPDATE: Bank of America Reinstates Coverage on Seattle Genetics as High Expectations are Priced In

Share:

In a report published Monday, Bank of America analyst Steve Byrne reinstated coverage on Seattle Genetics (NASDAQ: SGEN) with an Underperform rating and $46.00 price target.

In the report, Bank of America noted, “We are reinstating SGEN coverage with an Underperform rating and $46 PO. We believe the current share price reflects high expectations of significant label expansion for its key blood cancer drug Adcetris. We estimate Adcetris sales could triple from the current level by 2018 assuming several favorable data read-outs in the next 1-2 years in new indications. However, this 2018 forecast represents modest profitability by our estimates and an EV/sales ratio that is roughly twice the biotech sector median of 4x.

"Our DCF-derived NPV for Adcetris of $32/sh assumes $2bn of peak US risk-adj sales by the 2026 patent expiry, or 13-fold above 2013 levels. While favorable data in ~2018 from two first line studies (HL & MTCL) could drive upside, we see more downside risk from unfavorable trial results, competitive drugs in development (i.e. favorable early PD1 data in HL), or Adcetris' outlier price.”

Seattle Genetics closed on Friday at $54.92.

Latest Ratings for SGEN

DateFirmActionFromTo
Oct 2020Morgan StanleyMaintainsEqual-Weight
Oct 2020SVB LeerinkMaintainsOutperform
Oct 2020B of A SecuritiesMaintainsNeutral

View More Analyst Ratings for SGEN
View the Latest Analyst Ratings

 

Related Articles (SGEN)

View Comments and Join the Discussion!

Posted-In: Bank of America Steve ByrneAnalyst Color Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
CYBBFCitigroupDowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com